Members Trust Co Has $1.55 Million Position in Johnson & Johnson $JNJ

Key Points

• Members Trust Co increased its stake in Johnson & Johnson by 17.2%, holding a total of 10,146 shares worth approximately $1.55 million as of the end of the most recent quarter.
• Several analysts have raised their price targets for Johnson & Johnson, with Citigroup increasing it to $215.00 and Guggenheim upgrading the stock from a "neutral" to a "buy" rating.
• Johnson & Johnson announced a quarterly dividend of $1.30 scheduled to be paid on December 9th, representing a 2.7% dividend yield and a payout ratio of 50.19%.

Members Trust Co lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,146 shares of the company's stock after buying an additional 1,488 shares during the period. Members Trust Co's holdings in Johnson & Johnson were worth $1,550,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after buying an additional 1,170,120 shares during the period. Northern Trust Corp boosted its position in shares of Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after buying an additional 130,645 shares during the period. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Johnson & Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock worth $3,133,602,000 after acquiring an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Johnson & Johnson by 2.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after acquiring an additional 448,666 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on JNJ shares. Citigroup upped their target price on Johnson & Johnson from $213.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday, October 15th. Cowen reiterated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Bank of America upped their target price on Johnson & Johnson from $198.00 to $204.00 and gave the stock a "neutral" rating in a report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $199.05.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $192.81 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The stock's 50 day moving average is $181.64 and its 200-day moving average is $165.56. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $464.35 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 2.25 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.